Cannabis Bioscience International Holdings, Inc.

CBIHdata completeness 88%3 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'interestExpense'; no data for concept 'pretaxIncome'

i. The business — what you’d actually own

Figure	FY 2023	FY 2024	FY 2025
Revenue	$316,825¹	$248,841²	$303,022²
Net income	−$1.03M³	−$651,345⁴	−$548,820⁴
Operating cash flow	−$898,367⁵	−$479,382⁶	−$329,627⁶
Capital expenditure	—	—	—
Free cash flow (derived)	—	—	—
Total debt	$528,184⁷	$512,830⁸	$550,279⁸
Cash & equivalents	$8,913⁹	$755⁹	$12,952⁹
Diluted shares	9.00B	10.32B	10.72B

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$0

your share of equity

Profit it earned you last year

−$0

Free cash flow it threw off

—

Debt you’d be carrying

10 shares is a claim on −$0 of net worth that earned you −$0 last year, against $0 of debt.

iii. Is this a good business?

Moat signal · return on equity

— avg · 3y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

+19% shares · 3y

Share count is up 19% over 3 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts